Abstract
Aim:
To investigate the effects of phorbol 12-myristate 13-acetate (PMA), a PKC activator, on P-glycoprotein-mediated efflux of digoxin in two cell transport models.
Methods:
Caco-2 cells, wild MDCKII cells (MDCKII-WT) and MDCKII cells transfected stably with human MDR1-gene encoding P-gp (MDCKII-MDR1) were examined. Cell viability was evaluated with MTT assay. Bidirectional transport of digoxin was evaluated in these cells. Intracellular ATP level was measured using ATP assay. P-gp ATPase activity was analyzed using a Pgp-GloTM assay.
Results:
PMA (10 μmol/L) did not reduce the viability of the 3 types of cells. In Caco-2 and MDCKII-MDR1 cell monolayers, PMA (1, 10 and 100 nmol/L) dose-dependently inhibited the basolateral to apical transport of digoxin, but did not change the apical to basolateral transport. In addition, PMA did not affect both the basolateral to apical and apical to basolateral transport of digoxin in MDCKII-WT cell monolayer. In agreement with the above results, PMA dose-dependently reduced intracellular ATP level and stimulated P-gp ATPase activity in both Caco-2 and MDCKII-MDR1 cells. Verapamil (a positive control, 100 μmol/L) caused similar inhibition on digoxin efflux as PMA did, whereas 4α-PMA (a negative control, 100 nmol/L) had no effect.
Conclusion:
PMA significantly inhibited P-gp-mediated efflux of digoxin in both Caco-2 and MDCKII-MDR1 cell monolayers via PKC activation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Kumar YS, Adukondalu D, Sathish D, Vishnu YV, Ramesh G, Latha AB, et al. P-Glycoprotein-and cytochrome P-450-mediated herbal drug interactions. Drug Metabol Drug Interact 2010; 25: 3–16.
Chen KC, Li C, Uss AS . Prediction of oral drug absorption in humans — From cultured cell lines and experimental animals. Expert Opin Drug Metab Toxicol 2008; 4: 581–90.
Benet LZ, Cummins CL, Wu CY . Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2006; 277: 3–9.
Zhang LL, Lu L, Jin S, Jing XY, Yao D, Hu N, et al. Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2011; 32: 956–66.
Kim WY, Benet LZ . P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res 2004; 21: 1284–93.
Higgins CF . ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8: 67–113.
Mizuno N, Niwa T, Yotsumoto Y, Suqiyama Y . Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003; 55: 425–61.
Pang KS, Rodrigues AD, Peter R, eds. Enzyme- and Transporter-based drug-drug interactions, Progress and Future Challenges. New York: Springer; 2010. p 299–315.
Lin JH . Transporter-mediated drug interactions: clinical implication and in vitro assessment. Expert Opin Drug Metab Toxicol 2007; 3: 81–92.
Horn JR, Hansten PD . Drug interactions with digoxin: the role of P-glycoprotein. Pharm Times 2004. p 45–6.
Artursson P, Palm K, Luthman K . Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001; 46: 27–43.
Cogburn JN, Donovan MG, Schasteen CS . A model of human small intestinal absorptive cells. 1. Transport barrier. Pharm Res 1991; 8: 210–6.
Kataoka M, Masaoka Y, Yamazaki Y, Sakane T, Sezaki H, Yamashita S . In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs. Pharm Res 2002; 20: 1674–80.
Zhou W, Di LQ, Wang J, Shan JJ, Liu SJ, Ju WZ, et al. Intestinal absorption of forsythoside A in in situ single-pass intestinal perfusion and in vitro Caco-2 cell models. Acta Pharmacol Sin 2012; 33: 1069–79.
Ingels FM, Augustijns PF . Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2. J Pharm Sci 2003; 92: 1545–58.
Tang F, Horie K, Borchardt RT . Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 2002; 19: 765–72.
de Souza J, Benet LZ, Huang Y, Storpirtis S . Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci 2009; 98: 4413–9.
Blumberg PM . Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Cancer Res 1988; 48: 1–8.
Petiti JP, De Paul AL, Gutierrez S, Palmeri CM, Mukdsi JH, Torres AI . Activation of PKC epsilon induces lactotroph proliferation through ERK1/2 in response to phorbol ester. Mol Cell Endocrinol 2008; 289: 77–84.
Mason SA, Cozzi SJ, Pierce CJ, Pavey SJ, Parsons PG, Boyle GM . The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells. Invest New Drugs 2010; 28: 575–86.
O'Neill AK, Gallegos LL, Justilien V, Garcia EL, Leitges M, Fields AP, et al. Protein kinase Calpha promotes cell migration through a PDZ-dependent interaction with its novel substrate discs large homolog 1 (DLG1). J Biol Chem 2011; 286: 43559–68.
Eĭdus LKh, Emel'ianov MO, Korystova AF, Kublik LN, Shaposhnikova VV, Korystov IuN . Multidrug resistance increase of tumor cells at the effect of radiation and phorbol ether depends on protein kinase C and reactive oxygen species. Radiats Biol Radioecol 2010; 50: 37–41.
Fine RL, Patel J, Chabner BA . Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci U S A 1988; 85: 582–6.
Matsumoto T, Tani E, Yamaura I, Miyaji K, Kaba K . Effects of protein kinase C modulators on multidrug resistance in human glioma cells. Neurosurgery 1995; 36: 565–71.
Pondugula SR, Dong H, Chen T . Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression. Expert Opin Drug Metab Toxicol 2009; 5: 861–73.
Ding X, Staudinger JL . Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C. Biochem Pharmacol 2005; 69: 867–73.
Evers R, Zaman GJ, van Deemter L, Jansen H, Calafat J, Oomen LC, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996; 97: 1211–8.
Laitinen LA, Tammela PS, Galkin A, Vuorela HJ, Marvola ML, Vuorela PM . Effect of extracts of commonly consumed food supplements and food fraction on the permeability of drugs across Caco-2 cell monolayers. Pharm Res 2004; 21: 1904–16.
Simon S, Schubert R . Inhibitory effect of phospholipids on P-glycoprotein: cellular studies in Caco-2, MDCKII mdr1 and MDCKII wildtype cells and P-gp ATPase activity measurements. Biochim Biophys Acta 2012; 1821: 1211–23.
Xue XP, Huang M, Xiao HY, Qin XL, Huang L, Zhong GP, et al. Rapid and simultaneous measurement of midazolam, 1′-hydroxymidazolam and digoxin by liquid chromatography/tandem mass spectrometry: application to an in vivo study to simultaneously measure P-glycoprotein and cytochrome P450 3A activity. J Pharm Biomed Anal 2011; 55: 187–93.
Taub ME, Podila L, Ely D, Almeida L . Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: Influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos 2005; 33: 1679–87.
Sprague RS, Hanson MS, Achilleus D, Bowles EA, Stephenson AH, Sridharan M, et al. Rabbit erythrocytes release ATP and dilate skeletal muscle arterioles in the presence of reduced oxygen tension. Pharmacol Rep 2009; 61: 183–90.
Matsunaga T, Kose E, Yasuda S, Ise H, Ikeda U, Ohmori S . Determination of P-glycoprotein ATPase activity using luciferase. Biol Pharm Bull 2006; 29: 560–4.
Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215–36.
Taniqawara Y . Role of P-glycoprotein in drug disposition. The Drug Monit 2000. P 137–40.
Sharom FJ . Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 2006; 84: 979–92.
Oga EF, Sekine S, Shitara Y, Horie T . P-glycoprotein mediated efflux in Caco-2 cell monolayers: the influence of herbals on digoxin transport. J Ethnopharmacol 2012; 144: 612–7.
Oga EF, Sekine S, Shitara Y, Horie T . Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells. Am J Trop Med Hyg 2012; 87: 64–9.
Loo TW, Bartlett M, Clarke DM . Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments. Biochemistry 2007; 46: 9328–36.
Jones PM, George AM . Opening of the ADP-bound active site in the ABC transporter ATPase dimer: evidence for a constant contact, alternating sites model for the catalytic cycle. Proteins 2009; 75: 387–96.
Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R . Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000; 58: 624–32.
Dubielecka PM, Jaźwiec B, Potoczek S, Wróbel T, Miłoszewska J, Haus O, et al. Changes in spectrin organisation in leukaemic and lymphoid cells upon chemotherapy. Biochem Pharmacol 2005; 69: 73–85.
Barakat S, Gayet L, Dayan G, Labialle S, Lazar A, Oleinikov V, et al. Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis. Biochem J 2005; 388: 563–71.
Acknowledgements
This project was supported by the Natural Major Projects for Science and Technology Developments from the Science and Technology Ministry of China (Grant 2012ZX09506001–004) and National Natural Science Foundation of China (Grant 81001685).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Li, Yh., Bi, Hc., Huang, L. et al. Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models. Acta Pharmacol Sin 35, 283–291 (2014). https://doi.org/10.1038/aps.2013.157
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2013.157
Keywords
This article is cited by
-
OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition
Acta Pharmacologica Sinica (2016)
-
Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation
Acta Pharmacologica Sinica (2015)
